| 000 | 01595 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250514035739.0 | ||
| 264 | 0 | _c20020806 | |
| 008 | 200208s 0 0 eng d | ||
| 022 | _a1524-4628 | ||
| 024 | 7 |
_a10.1161/01.str.0000020094.08790.49 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOrgogozo, Jean-Marc | |
| 245 | 0 | 0 |
_aEfficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). _h[electronic resource] |
| 260 |
_bStroke _cJul 2002 |
||
| 300 |
_a1834-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCognition _xdrug effects |
| 650 | 0 | 4 |
_aDementia, Vascular _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aDizziness _xetiology |
| 650 | 0 | 4 |
_aDopamine Agents _xadverse effects |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMemantine _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aN-Methylaspartate _xantagonists & inhibitors |
| 650 | 0 | 4 | _aNeuropsychological Tests |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRigaud, Anne-Sophie | |
| 700 | 1 | _aStöffler, Albrecht | |
| 700 | 1 | _aMöbius, Hans-Jorgen | |
| 700 | 1 | _aForette, Françoise | |
| 773 | 0 |
_tStroke _gvol. 33 _gno. 7 _gp. 1834-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/01.str.0000020094.08790.49 _zAvailable from publisher's website |
| 999 |
_c11996840 _d11996840 |
||